Table 2.
Patient demographics and baseline clinical characteristics in the efficacy-evaluable population
| Characteristic | Vehicle (n = 244) | 0.75% Ruxolitinib cream (n = 483) | 1.5% Ruxolitinib cream (n = 481) | Total (N = 1208) |
|---|---|---|---|---|
| Age, median (range), years | 34 (12–82) | 34 (12–85) | 31 (12–85) | 32 (12–85) |
| Age category, n (%), years | ||||
| 12–17 | 43 (17.6) | 106 (21.9) | 87 (18.1) | 236 (19.5) |
| ≥ 18 | 201 (82.4) | 377 (78.1) | 394 (81.9) | 972 (80.5) |
| Female, n (%) | 154 (63.1) | 292 (60.5) | 293 (60.9) | 739 (61.2) |
| Race, n (%) | ||||
| White | 164 (67.2) | 328 (67.9) | 337 (70.1) | 829 (68.6) |
| Black | 61 (25.0) | 118 (24.4) | 113 (23.5) | 292 (24.2) |
| Asian | 10 (4.1) | 16 (3.3) | 20 (4.2) | 46 (3.8) |
| Other | 9 (3.7) | 21 (4.3) | 11 (2.3) | 41 (3.4) |
| Region, n (%) | ||||
| North America | 172 (70.5) | 342 (70.8) | 341 (70.9) | 855 (70.8) |
| Europe | 72 (29.5) | 141 (29.2) | 140 (29.1) | 353 (29.2) |
| BSA, mean (SD), % | 9.5 (5.4) | 9.7 (5.2) | 9.4 (5.2) | 9.6 (5.2) |
| Baseline EASI, mean (SD) | 7.8 (4.8) | 8.1 (4.9) | 7.8 (4.8) | 7.9 (4.9) |
| Baseline IGA, n (%) | ||||
| 2 | 64 (26.2) | 125 (25.9) | 123 (25.6) | 312 (25.8) |
| 3 | 180 (73.8) | 358 (74.1) | 358 (74.4) | 896 (74.2) |
| Itch NRS score, mean (SD) | 5.2 (2.5) | 5.1 (2.4) | 5.1 (2.5) | 5.1 (2.4) |
| ≥ 4, n (%) | 158 (64.8) | 313 (64.8) | 307 (63.8) | 778 (64.4) |
| PROMIS sleep disturbance score, mean (SD) | 18.7 (5.8) | 19.1 (6.1) | 19.0 (6.1) | 18.9 (6.1) |
| PROMIS sleep-related impairment score, mean (SD) | 16.8 (6.1) | 17.3 (6.2) | 17.4 (6.2) | 17.2 (6.2) |
| Duration of disease, median (range), years | 16.5 (0.8–79.1) | 14.8 (0.1–68.8) | 15.9 (0–69.2) | 15.3 (0–79.1) |
| Number of flares in the past 12 months, mean (SD) | 7.3 (26.0) | 5.1 (6.7) | 5.8 (17.9) | 5.8 (16.8) |
BSA body surface area, EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, NRS numeric rating scale, PROMIS Patient-Reported Outcomes Measurement Information System, SD standard deviation